Intelligent Bio Solutions Inc. (Nasdaq: INBS) anticipates a 16% revenue growth in the fiscal fourth quarter compared to the previous quarter and the same quarter last year. They have been focusing on securing FDA clearance and upgrading systems for global readiness.

The company has submitted an FDA 510(k) application for their opiate test system and made upgrades to their Intelligent Fingerprinting Drug Screening System to support global adoption. They have also launched localized websites and improved CRM workflows for better engagement in Europe, the Middle East, and Latin America.

Preliminary unaudited results show that Intelligent Bio Solutions Inc. expects a 16% revenue increase in the fiscal fourth quarter of 2025, driven by demand for higher-margin cartridge sales and account growth. These results are subject to adjustments based on the completion of the year-end financial close process.

Intelligent Bio Solutions Inc. is a medical technology company offering non-invasive testing solutions. Their Intelligent Fingerprinting Drug Screening System uses fingerprint sweat analysis for quick drug testing. The company serves various industries outside the US, including construction, manufacturing, transport, mining, drug treatment, and more.

For more information, visit the Intelligent Bio Solutions Inc. website at https://ibs.inc/. The company has made forward-looking statements regarding their ability to develop and commercialize their tests successfully. They are also focused on securing regulatory approvals and partnerships, but acknowledge potential risks and uncertainties.

Read more at GlobeNewswire: Intelligent Bio Solutions Announces Preliminary Fiscal